Peptides: What they are, where we are, and how we got here.

How did we get to a place where injectable peptides, which often carry way more risk than many prescription medications, can end up in the hands of anyone with internet access?!

That question has been sitting with me for months. So let’s back up.

What a peptide actually is

A peptide is just a signaling molecule, typically 2 to 50 amino acids long. Some are so commonplace you don’t even register them as peptides: insulin, for one. Growth hormone, another (my favorite soccer player took it as a kid). And in recent years, the blockbuster weight-loss drugs have put peptides in nearly every household: liraglutide (Victoza), semaglutide (Wegovy), tirzepatide (Zepbound). You already know this family better than you think.

Where I come in

Around the pandemic, a quiet swell of interest began among clinicians from all kinds of backgrounds, coalescing around a shared curiosity and a steadfast desire to do better for their patients. I was one of them. I sat through meetings, masterclasses, and one-on-ones with clinicians on the leading edge: physicians uncovering peptides with either clinical data from other countries or strong preclinical data and excellent biological plausibility, worth considering in complex cases when the risk-benefit made sense. 

Fast-forward to now, and the word peptide has become loaded. You can’t open a magazine or scroll social media without hitting it.  And people have opinions…lots of them.

The shift I’ve watched happen

In the last few months, patients have started bringing peptides to me unprompted. “What peptide do you think would be good for me?” “I see peptides online, should I try one?” “All my friends are doing peptide therapy, I want in.”

Part of me is heartened. These conversations are happening with a trusted clinician, which is exactly where they belong. But another part of me is genuinely uneasy at how normal it’s become to buy an injectable peptide from a TikTok link, how casually that decision gets made. I live in the weeds of exactly these calls: when to step outside an algorithmic guideline, when a non-FDA-approved compound might be worth considering. That kind of judgment is built on years of training, close reading of the literature, real physiology, and honest risk assessment. It is not built on a comment section.

How we got here

The short answer: unrelenting patient demand.

In the years leading up to 2023, people began noticing real benefits from certain non-pharma-sourced peptides, and their use crept into the mainstream, even among licensed physicians. Out of caution, the US government placed a group of these peptides, including BPC-157, GHK-Cu, TB-500, CJC-1295/Ipamorelin, and many more, into Category 2, which barred licensed compounding pharmacies from making them.

The gray market filled the gap almost immediately. Influencers started speaking with the same confidence as trained clinicians, on Instagram, on TikTok, everywhere.

I’ve heard stories of teenagers buying peptides online to “look hotter.” I still don’t have words for that one.

I was glad to see a regulatory counter-push in February 2026 to move 14  peptides back to Category 1, including some you may the name of often like BPC-157, Thymosin Alpha-1, TB-500, MOTs-c, CJC-1295/Ipamorelin, Selank, Semax, KPV, Epitalon and more.. 

Here’s why that matters: if a peptide can legally be compounded by a licensed pharmacy under state regulation, we get visibility into purity, potency, and contaminants: the exact questions that matter most before anything goes into a body. The previous regulation was reacting to the risk of these compounds existing at all, which was reasonable. But there’s a subsequent risk that it missed: what happens when literally anyone can manufacture and sell them to the public, with zero oversight.

Last week, a group of physicians brought reams of data to the FDA in defense of returning peptide sourcing to licensed hands, and their case appears to have landed: the advisory panel voted to recommend six of seven of the peptides under review (BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax) for a return to Category 1. There’s still red tape ahead, but I support the direction, and I’m grateful to the colleagues who showed up with patient safety as their north star.

Where that leaves you

Right now there are close to 60 peptides in active clinical discussion among clinicians and scientists in the know. Some have strong evidence behind them. Some have only preclinical or anecdotal support. That range matters.

So no, please don’t take whatever peptide your friend bought online. But do stay curious. If you’re thinking about it, bring these questions to your doctor rather than a group chat:

• Is this peptide sourced from a licensed, state-regulated compounding pharmacy, not a “research use only” vendor?  Is there a Certificate of Analysis?
• What data actually exists for this specific peptide, and for my specific situation?
• What would monitoring look like if I started, and how would we know it’s working, or not?
• What are the perimeters and limits to keep me safe clinically? 

Whether any of these compounds are right for you should be an individualized

References:

https://www.medscape.com/viewarticle/gray-market-peptides-so-much-hype-so-little-data-2026a1000dzg

https://pmc.ncbi.nlm.nih.gov/articles/PMC11053547

https://pubmed.ncbi.nlm.nih.gov/41155565

https://pmc.ncbi.nlm.nih.gov/articles/PMC12164287

https://pubmed.ncbi.nlm.nih.gov/18061177

https://pubmed.ncbi.nlm.nih.gov/41476424

https://pubmed.ncbi.nlm.nih.gov/30225715

https://pubmed.ncbi.nlm.nih.gov/36761202

https://pubmed.ncbi.nlm.nih.gov/40141333

https://www.nytimes.com/2025/11/18/well/live/peptide-therapy-skin-muscle-longevity.html

https://www.raps.org/resource/fda-considers-adding-a-dozen-peptides-to-its-bulk-drug-compounding-list.html

https://abcnews.com/Health/fda-advisers-narrowly-vote-add-6-peptides-drug/story?id=135064915